Search

Your search keyword '"Ito, Tomoki"' showing total 454 results
Start Over Author "Ito, Tomoki" Publication Type Academic Journals
454 results on '"Ito, Tomoki"'

1. Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan

Author

Sugimoto, Yuka, Nagaharu, Keiki, Ohya, Eiko, Ohishi, Kohshi, Tawara, Isao, Ito, Tomoki, Gotoh, Akihiko, Nakamae, Mika, Kimura, Fumihiko, Koike, Michiaki, Kirito, Keita, Wada, Hideho, Usuki, Kensuke, Tanaka, Takayuki, Mori, Takehiko, Wakita, Satoshi, Saito, Toshiki I., Saito, Akiko M., Shimoda, Kazuya, Kurokawa, Toshiro, Tomita, Akihiro, Edahiro, Yoko, Hashimoto, Yoshinori, Kiyoi, Hitoshi, Akashi, Koichi, Matsumura, Itaru, Takenaka, Katsuto, and Komatsu, Norio

Published
2024
Full Text
View/download PDF

2. The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patients

Author

Shimazu, Yutaka, Kanda, Junya, Takakuwa, Teruhito, Onda, Yoshiyuki, Fukushima, Kentaro, Hotta, Masaaki, Fuchida, Shin-ichi, Uoshima, Nobuhiko, Shimura, Yuji, Tanaka, Hirokazu, Ohta, Kensuke, Shibayama, Hirohiko, Kosugi, Satoru, Yagi, Hideo, Yoshihara, Satoshi, Hosen, Naoki, Ito, Tomoki, Shimazaki, Chihiro, Matsumura, Itaru, Kuroda, Junya, Takaori-Kondo, Akifumi, and Hino, Masayuki

Published
2024
Full Text
View/download PDF

3. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

Author

Nakamura, Naokazu, Arima, Nobuyoshi, Takakuwa, Teruhito, Yoshioka, Satoshi, Imada, Kazunori, Fukushima, Kentaro, Hotta, Masaaki, Fuchida, Shin-ichi, Kanda, Junya, Uoshima, Nobuhiko, Shimura, Yuji, Tanaka, Hirokazu, Ohta, Kensuke, Kosugi, Satoru, Yagi, Hideo, Yoshihara, Satoshi, Yamamura, Ryosuke, Adachi, Yoko, Hanamoto, Hitoshi, Shibayama, Hirohiko, Hosen, Naoki, Ito, Tomoki, Shimazaki, Chihiro, Takaori-Kondo, Akifumi, Kuroda, Junya, Matsumura, Itaru, and Hino, Masayuki

Published
2024
Full Text
View/download PDF

5. Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis

Author

Nagaharu, Keiki, Ohya, Eiko, Edahiro, Yoko, Hashimoto, Yoshinori, Ito, Tomoki, Gotoh, Akihiko, Nakamae, Mika, Kimura, Fumihiko, Koike, Michiaki, Kirito, Keita, Wada, Hideho, Usuki, Kensuke, Tanaka, Takayuki, Mori, Takehiko, Wakita, Satoshi, Saito, Toshiki I., Saito, Akiko M., Shimoda, Kazuya, Kurokawa, Toshiro, Tomita, Akihiro, Kiyoi, Hitoshi, Akashi, Koichi, Matsumura, Itaru, Takenaka, Katsuto, Komatsu, Norio, Ohishi, Kohshi, Tawara, Isao, and Sugimoto, Yuka

Published
2024
Full Text
View/download PDF

6. Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in Japan

Author

Usuki, Kensuke, Kameda, Takuro, Kawano, Noriaki, Ito, Tomoki, Hashimoto, Yoshinori, Shide, Kotaro, Kawano, Hiroshi, Sekine, Masaaki, Toyama, Takanori, Iizuka, Hiromitsu, Sato, Seiichi, Takeuchi, Masanori, Ishizaki, Junzo, Maeda, Kouichi, Nakai, Michikazu, Yamashita, Kiyoshi, Kubuki, Yoko, and Shimoda, Kazuya

Published
2024
Full Text
View/download PDF

8. Correction to: Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis

Author

Nagaharu, Keiki, Ohya, Eiko, Edahiro, Yoko, Hashimoto, Yoshinori, Ito, Tomoki, Gotoh, Akihiko, Nakamae, Mika, Kimura, Fumihiko, Koike, Michiaki, Kirito, Keita, Wada, Hideho, Usuki, Kensuke, Tanaka, Takayuki, Mori, Takehiko, Wakita, Satoshi, Saito, Toshiki I., Saito, Akiko M., Shimoda, Kazuya, Kurokawa, Toshiro, Tomita, Akihiro, Kiyoi, Hitoshi, Akashi, Koichi, Matsumura, Itaru, Takenaka, Katsuto, Komatsu, Norio, Ohishi, Kohshi, Tawara, Isao, and Sugimoto, Yuka

Published
2024
Full Text
View/download PDF

9. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

Author

Shimazu, Yutaka, Kanda, Junya, Onda, Yoshiyuki, Fuchida, Shin-ichi, Ohta, Kensuke, Shimura, Yuji, Kosugi, Satoru, Yamamura, Ryosuke, Matsuda, Mitsuhiro, Hanamoto, Hitoshi, Adachi, Yoko, Anzai, Naoyuki, Hotta, Masaaki, Fukushima, Kentaro, Yagi, Hideo, Yoshihara, Satoshi, Tanaka, Yasuhiro, Takakuwa, Teruhito, Tanaka, Hirokazu, Shibayama, Hirohiko, Uoshima, Nobuhiko, Hosen, Naoki, Ito, Tomoki, Shimazaki, Chihiro, Matsumura, Itaru, Kuroda, Junya, Takaori-Kondo, Akifumi, and Hino, Masayuki

Published
2024
Full Text
View/download PDF

10. Prevalence and causes of subacute cough in Japan

Author

Ishiura, Yoshihisa, Fujimura, Masaki, Ogawa, Haruhiko, Hara, Johsuke, Shintani, Hiromoto, Hozawa, Soichiro, Atsuta, Ryo, Fukumitsu, Kensuke, Inoue, Hideki, Shioya, Takanobu, Muraki, Masato, Amemiya, Tokunao, Ohkura, Noriyuki, Oribe, Yoshitaka, Tanaka, Hiroshi, Yamada, Takechiyo, Toyoshima, Mikio, Fujimori, Katsuya, Ishizuka, Tamotsu, Kagaya, Manabu, Suzuki, Takeshi, Kita, Toshiyuki, Nishi, Koichi, Ueda, Akihito, Miyata, Yoshito, Kitada, Junya, Yamamura, Kenta, Abo, Miki, Takeda, Norihisa, Shirai, Toshihiro, Tajiri, Tomoko, Yoshihara, Shigemi, Akamatsu, Taisuke, Sawaguchi, Hirochiyo, Nagano, Tatsuya, Hanada, Soichiro, Masuda, Sawako, Ohmichi, Mitsuhide, Ito, Tomoki, Sagara, Hironori, Matsumoto, Hisako, and Niimi, Akio

Published
2025
Full Text
View/download PDF

11. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum

Author

Shimura, Yuji, Shibayama, Hirohiko, Nakaya, Aya, Yamamura, Ryosuke, Imada, Kazunori, Kaneko, Hitomi, Hanamoto, Hitoshi, Fuchida, Shin-ichi, Tanaka, Hirokazu, Kosugi, Satoru, Kiyota, Miki, Matsui, Toshimitsu, Kanda, Junya, Iida, Masato, Matsuda, Mitsuhiro, Uoshima, Nobuhiko, Shibano, Masaru, Karasuno, Takahiro, Hamada, Tsuneyoshi, Ohta, Kensuke, Ito, Tomoki, Yagi, Hideo, Yoshihara, Satoshi, Shimazaki, Chihiro, Nomura, Shosaku, Hino, Masayuki, Takaori-Kondo, Akifumi, Matsumura, Itaru, Kanakura, Yuzuru, and Kuroda, Junya

Published
2023
Full Text
View/download PDF

12. Prevalence and causes of chronic cough in Japan

Author

Ishiura, Yoshihisa, Fujimura, Masaki, Ogawa, Haruhiko, Hara, Johsuke, Shintani, Hiromoto, Hozawa, Soichiro, Atsuta, Ryo, Fukumitsu, Kensuke, Inoue, Hideki, Shioya, Takanobu, Muraki, Masato, Amemiya, Tokunao, Ohkura, Noriyuki, Oribe, Yoshitaka, Tanaka, Hiroshi, Yamada, Takechiyo, Toyoshima, Mikio, Fujimori, Katsuya, Ishizuka, Tamotsu, Kagaya, Manabu, Suzuki, Takeshi, Kita, Toshiyuki, Nishi, Koichi, Ueda, Akihito, Miyata, Yoshito, Kitada, Junya, Yamamura, Kenta, Abo, Miki, Takeda, Norihisa, Shirai, Toshihiro, Tajiri, Tomoko, Yoshihara, Shigemi, Akamatsu, Taisuke, Sawaguchi, Hirochiyo, Nagano, Tatsuya, Hanada, Soichiro, Masuda, Sawako, Ohmichi, Mitsuhide, Ito, Tomoki, Sagara, Hironori, Matsumoto, Hisako, and Niimi, Akio

Published
2024
Full Text
View/download PDF

16. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Author

Shimazu, Yutaka, Kanda, Junya, Kosugi, Satoru, Ito, Tomoki, Kaneko, Hitomi, Imada, Kazunori, Shimura, Yuji, Fuchida, Shin-ichi, Fukushima, Kentaro, Tanaka, Hirokazu, Yoshihara, Satoshi, Ohta, Kensuke, Uoshima, Nobuhiko, Yagi, Hideo, Shibayama, Hirohiko, Yamamura, Ryosuke, Tanaka, Yasuhiro, Uchiyama, Hitoji, Onda, Yoshiyuki, Adachi, Yoko, Hanamoto, Hitoshi, Takahashi, Ryoichi, Matsuda, Mitsuhiro, Miyoshi, Takashi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, and Kuroda, Junya

Published
2023
Full Text
View/download PDF

18. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

Author

Fillitz, Michael, Knoebl, Paul, Meers, Stef, Amine, Ismail Mohamad, Gumulec, Jaromir, Hlusi, Antonin, Mayer, Jiri, Quittet, Philippe, Viallard, Jean-Francois, Betaneli, Magdana, Datikashvili-David, Irine, Iosava, Genadi, Makhaldiani, Levan, Rejto, Laszlo, Sharashenidze, Nino, Groepper, Stefanie, Röth, Alexander, Hamed, Aryan, Illes, Arpad, Carpenedo, Monica, Artoni, Andrea, Bocchia, Monica, Gamberi, Barbara, Borchiellini, Alessandra, Oliva, Esther Natalie, Patriarca, Andrea, Tomassetti, Simona, Miyakawa, Yoshitaka, Ando, Kiyoshi, Handa, Hiroshi, Katsutani, Shinya, Nishiwaki, Kaichi, Ito, Shoko, Ito, Tomoki, de Boer, Fransien, Jansen, A.J. Gerard, Ciepluch, Hanna, Fornagiel, Szymon, Grosicki, Sebastian, Soroka-Wojtaszko, Maria, Trelinski, Jacek, Bakirov, Bulat, Borisenkova, Elena, Volodicheva, Elena, Shatokhin, Yuri, Proydakov, Andrey, Alonso, Maria Aranzazu, Mingot-Castellano, María Eva, Sanchez-Gonzalez, Blanca, Valcarcel Ferreiras, David, Ayli, Meltem, Hacibekiroglu, Tuba, Demir, Ahmet Muzaffer, Nalçaci, Meliha, Sonmez, Mehmet, Tombak, Anil, Toprak, Selami Kocak, Turgut, Burhan, Vural, Filiz, Yagci, Munci, Altuntas, Fevzi, Turgut, Mehmet, Kaya, Emin, Romanyuk, Nataliya, McDonald, Vickie, Kazmi, Syed Rashid Saeed, Broome, Catherine, Cataland, Spero, Doshi, Ketan, Lentz, Steven R., Boxer, Michael, Rosenberg, Richard, Broome, Catherine M, Kuter, David J, Al-Samkari, Hanny, Bussel, James B, Godar, Marie, Ayguasanosa, Jaume, De Beuf, Kristof, Rodeghiero, Francesco, Michel, Marc, and Newland, Adrian

Published
2023
Full Text
View/download PDF

19. Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study

Author

Edahiro, Yoko, Ito, Tomoki, Gotoh, Akihiko, Nakamae, Mika, Kimura, Fumihiko, Koike, Michiaki, Kirito, Keita, Wada, Hideho, Usuki, Kensuke, Tanaka, Takayuki, Mori, Takehiko, Wakita, Satoshi, Saito, Toshiki I., Kada, Akiko, Saito, Akiko M., Shimoda, Kazuya, Sugimoto, Yuka, Kurokawa, Toshiro, Tomita, Akihiro, Hashimoto, Yoshinori, Akashi, Koichi, Matsumura, Itaru, Takenaka, Katsuto, and Komatsu, Norio

Published
2022
Full Text
View/download PDF

21. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy

Author

Yoshida, Chikashi, Kondo, Takeshi, Ito, Tomoki, Kizaki, Masahiro, Yamamoto, Kazuhiko, Miyamoto, Toshihiro, Morita, Yasuyoshi, Eto, Tetsuya, Katsuoka, Yuna, Takezako, Naoki, Uoshima, Nobuhiko, Imada, Kazunori, Ando, Jun, Komeno, Takuya, Mori, Akio, Ishikawa, Yuichi, Satake, Atsushi, Watanabe, Junichi, Kawakami, Yoshiko, Morita, Tetsuo, Taneike, Ikue, Nakayama, Masahiko, Duan, Yinghui, Garbayo Guijarro, Belen, Delgado, Alexander, Llamas, Cynthia, and Kiyoi, Hitoshi

Published
2022
Full Text
View/download PDF

22. Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study

Author

Hashimoto, Yoshinori, Ito, Tomoki, Gotoh, Akihiko, Nakamae, Mika, Kimura, Fumihiko, Koike, Michiaki, Kirito, Keita, Wada, Hideho, Usuki, Kensuke, Tanaka, Takayuki, Mori, Takehiko, Wakita, Satoshi, Saito, Toshiki I., Kada, Akiko, Saito, Akiko M., Shimoda, Kazuya, Sugimoto, Yuka, Kurokawa, Toshiro, Tomita, Akihiro, Edahiro, Yoko, Akashi, Koichi, Matsumura, Itaru, Takenaka, Katsuto, and Komatsu, Norio

Published
2022
Full Text
View/download PDF

26. Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day

Author

Hashimoto, Yoshinori, Ito, Tomoki, Tanaka, Yasuhiro, Nakaya, Aya, Fujita, Shinya, Satake, Atsushi, Nakanishi, Takahisa, Konishi, Akiko, Hotta, Masaaki, Yoshimura, Hideaki, Ishii, Kazuyoshi, Hashimoto, Akiko, Kondo, Toshinori, Omura, Hiromi, Shinzato, Isaku, Tanaka, Takayuki, and Nomura, Shosaku

Published
2020
Full Text
View/download PDF

30. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study).

Author

Abe, Yu, Kubonishi, Shiro, Ri, Masaki, Iino, Masaki, Sunami, Kazutaka, Ito, Tomoki, Fukaya, Masafumi, Kitano, Toshiyuki, Ikeda, Sho, Ota, Shuichi, Kuroi, Taiga, Iriyama, Noriyoshi, Jo, Tatsuro, Adachi, Masaaki, Akahane, Daigo, Kai, Tatsuyuki, Kohara, Yoichi, Kadowaki, Norimitsu, and Katayama, Teruaki

Abstract

Background: The ARROW study demonstrated that once-weekly carfilzomib and dexamethasone (wKd) therapy significantly prolonged progression-free survival compared with twice-weekly carfilzomib and dexamethasone therapy in relapsed or refractory multiple myeloma patients. Aim: To describe the treatment patterns, effectiveness and safety of wKd therapy in real-world settings in Japan. Methods: We investigated data from the medical records of 126 Japanese patients with relapsed or refractory multiple myeloma. Results: The overall response rate was 66.3%. The median progression-free survival was 9.5 months. The incidence of treatment-emergent adverse events of any grade and grade ≥3 were 45.8 and 20.8%, respectively. Conclusion: There were no new or unexpected safety signals in this study. This study demonstrated the effectiveness and safety profiles of wKd therapy in Japan. Carfilzomib became available for daily clinical practice as a drug for cancer of bone marrow (multiple myeloma) that comes back or does not respond to previous drug (relapsed or refractory). This drug was approved in the USA in 2012, and in Japan in 2016. In this study, we looked at how once-weekly carfilzomib works and how safe it is in real-life situations in Japan. We screened 126 patients with relapsed or refractory multiple myeloma in Japan. The median age of the patients was 70 years, with 25% being over 75 years. This study also included some patients who were not in the best overall health, had a history of many treatments or had heart complications. In 66.3% of patients, the cancer had disappeared or the extent of the cancer had reduced after treatment. Side effects and serious side effects occurred in 45.8 and 14.2% of patients, respectively. The most common side effects were low levels of blood platelets (9.2%), high blood pressure (5.8%), loose or watery stools (5.0%), fever (5.0%), and low levels of red blood cells (4.2%). Heart disorders occurred in five patients. But all patients recovered or improved with treatment such as blood pressure lowering drugs and diuretics. These results showed that once-weekly carfilzomib works well and is safe in real-world settings in Japan. This information can help us think about how to pick the right patients and handle heart disease risks when using carfilzomib treatment. Once-weekly carfilzomib in combination with dexamethasone (wKd) therapy is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). Although the ARROW study demonstrated that wKd therapy significantly prolonged progression-free survival compared with twice-weekly carfilzomib and dexamethasone (20/27 mg/m2) therapy in RRMM patients, there are few reports based on real-world data for wKd therapy in Japanese patients. This Weekly-CAR study is an observational study that evaluated real-world clinical data on wKd treatment in Japanese patients with RRMM. In this study, the overall response rate and median progression-free survival were 66.3% and 9.5 months, respectively. There were no new or unexpected safety signals in this study. Additionally, this study demonstrated the effectiveness and safety in patients who were not recruitable to the clinical trial of wKd therapy, for example those with an Eastern Cooperative Oncology Group performance status ≥2, or those with 1 or ≥4 prior regimens. These data demonstrated the effectiveness and safety profiles of wKd therapy in real-world settings in Japan. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production.

Author

Cao, Wei, Rosen, David B, Ito, Tomoki, Bover, Laura, Bao, Musheng, Watanabe, Gokuran, Yao, Zhengbin, Zhang, Li, Lanier, Lewis L, and Liu, Yong-Jun

Subjects
Dendritic Cells, Humans, Interferons, Receptors, IgE, Receptors, Immunologic, Toll-Like Receptors
Abstract

Immunoglobulin-like transcripts are a family of inhibitory and stimulatory cell surface immune receptors. Transcripts for one member of this family, ILT7, are selectively expressed in human plasmacytoid dendritic cells (pDCs). We demonstrate here that ILT7 protein associates with the signal adapter protein Fc epsilonRI gamma to form a receptor complex. Using an anti-ILT7 monoclonal antibody, we show that ILT7 is expressed specifically on human pDCs, but not on myeloid dendritic cells or other peripheral blood leukocytes. Cross-linking of ILT7 resulted in phosphorylation of Src family kinases and Syk kinase and induced a calcium influx in freshly isolated pDCs, which was blocked by Src family and Syk kinases inhibitors, thus indicating the activation of an immunoreceptor-based tyrosine activation motif-mediated signaling pathway. ILT7 cross-linking on CpG or influenza virus-stimulated primary pDCs inhibited the transcription and secretion of type I interferon and other cytokines. Therefore, the ILT7-Fc epsilonRI gamma receptor complex negatively regulates the innate immune functions of human pDCs.

Published
2006

39. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilon RI gamma inhibits Toll-like receptor-induced interferon production

Author

Cao, Wei, Rosen, David B, Ito, Tomoki, Bover, Laura, Bao, Musheng, Watanabe, Gokuran, Yao, Zhengbin, Zhang, Li, Lanier, Lewis L, and Liu, Yong-Jun

Abstract

Immunoglobulin-like transcripts are a family of inhibitory and stimulatory cell surface immune receptors. Transcripts for one member of this family, ILT7, are selectively expressed in human plasmacytoid dendritic cells ( pDCs). We demonstrate here that ILT7 protein associates with the signal adapter protein Fc epsilon RI gamma to form a receptor complex. Using an anti-ILT7 monoclonal antibody, we show that ILT7 is expressed specifically on human pDCs, but not on myeloid dendritic cells or other peripheral blood leukocytes. Cross-linking of ILT7 resulted in phosphorylation of Src family kinases and Syk kinase and induced a calcium influx in freshly isolated pDCs, which was blocked by Src family and Syk kinases inhibitors, thus indicating the activation of an immunoreceptor-based tyrosine activation motif mediated signaling pathway. ILT7 cross-linking on CpG or influenza virus-stimulated primary pDCs inhibited the transcription and secretion of type I interferon and other cytokines. Therefore, the ILT7-Fc epsilon RI gamma receptor complex negatively regulates the innate immune functions of human pDCs.

Published
2006

45. Aspiration pneumonia was the most frequent cause of death in older patients with SARS‐CoV‐2 omicron‐related pneumonia in Japan.

Author

Miyashita, Naoyuki, Nakamori, Yasushi, Ogata, Makoto, Fukuda, Naoki, Yamura, Akihisa, and Ito, Tomoki

Subjects
MICROBIAL sensitivity tests, ASPIRATION pneumonia, CAUSES of death, REVERSE transcriptase polymerase chain reaction, VIRAL pneumonia, GENETIC mutation, COVID-19, MIXED infections, DEGLUTITION disorders, DISEASE complications, OLD age
Abstract

The article presents a study which investigated the frequency of bacterial coinfection and aspiration and cause of death in older patients hospitalized for COVID-19-related pneumonia. Topics discussed include conditions present in COVID-19 pneumonia, underlying conditions and clinical findings in older patients hospitalized for COVID-19-related pneumonia, and association between advanced age and medical comorbidities and aspiration pneumonia in Japan.

Published
2024
Full Text
View/download PDF

46. A prospective compound screening contest identified broader inhibitors for Sirtuin 1

Author

Chiba, Shuntaro, Ohue, Masahito, Gryniukova, Anastasiia, Borysko, Petro, Zozulya, Sergey, Yasuo, Nobuaki, Yoshino, Ryunosuke, Ikeda, Kazuyoshi, Shin, Woong-Hee, Kihara, Daisuke, Iwadate, Mitsuo, Umeyama, Hideaki, Ichikawa, Takaaki, Teramoto, Reiji, Hsin, Kun-Yi, Gupta, Vipul, Kitano, Hiroaki, Sakamoto, Mika, Higuchi, Akiko, Miura, Nobuaki, Yura, Kei, Mochizuki, Masahiro, Ramakrishnan, Chandrasekaran, Thangakani, A. Mary, Velmurugan, D., Gromiha, M. Michael, Nakane, Itsuo, Uchida, Nanako, Hakariya, Hayase, Tan, Modong, Nakamura, Hironori K., Suzuki, Shogo D., Ito, Tomoki, Kawatani, Masahiro, Kudoh, Kentaroh, Takashina, Sakurako, Yamamoto, Kazuki Z., Moriwaki, Yoshitaka, Oda, Keita, Kobayashi, Daisuke, Okuno, Tatsuya, Minami, Shintaro, Chikenji, George, Prathipati, Philip, Nagao, Chioko, Mohsen, Attayeb, Ito, Mari, Mizuguchi, Kenji, Honma, Teruki, Ishida, Takashi, Hirokawa, Takatsugu, Akiyama, Yutaka, and Sekijima, Masakazu

Published
2019
Full Text
View/download PDF

48. Functional decline at 1 year in hospitalized elderly pneumonia with SARS‐CoV‐2 Omicron variant: Comparison with the ancestral strain and Alpha variant.

Author

Miyashita, Naoyuki, Nakamori, Yasushi, Ogata, Makoto, Fukuda, Naoki, Yamura, Akihisa, and Ito, Tomoki

Subjects
SARS-CoV-2 Omicron variant, PNEUMONIA, COVID-19, OLDER people, OLDER patients, ASPIRATION pneumonia
Abstract

In the SARS‐CoV‐2 Omicron period, the pattern of pneumonia changed from primarily viral pneumonia to pneumonia mixed with bacteria in the elderly. We investigated functional outcomes at 1 year after hospital discharge in patients with primary Omicron pneumonia and pneumonia mixed with bacteria, mainly aspiration pneumonia. Functional decline rates calculated using the Barthel Index at 1 year after hospital discharge were significantly higher in the pneumonia mixed with bacteria group than the primary viral pneumonia group (42.6% vs. 20.5%, p < 0.0001). It is necessary to consider early rehabilitation and treatment in elderly patients even when the predominant strain is the Omicron variant. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Risk of Atherosclerosis Due to HMGB1-dependent Platelet-derived Microparticles in Patients with Type 2 Diabetes Mellitus.

Author

Nomura, Shosaku, Taniura, Takehito, Ichikawa, Jun, Iwama, Ayako, and Ito, Tomoki

Subjects
HIGH mobility group proteins, TYPE 2 diabetes, CD26 antigen, MULTIPLE regression analysis, PLASMINOGEN activators
Abstract

We measured high mobility group box 1 protein (HMGB1) and platelet-derived microparticles (PDMP) in blood samples from patients with untreated type 2 diabetes mellitus (T2DM). We examined the effects of a combination of sodium/glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. Multiple regression analysis of HMGB1 was conducted on data from 252 patients in our previously reported T2DM-related clinical study. The results revealed significant correlations between HMGB1 and PDMP, soluble CD40 ligand, plasminogen activator inhibitor-1, and soluble E-selectin in multivariate analysis. Based on the HMGB1 levels before treatment with combination, 46 T2DM patients in the study were classified into two groups, high and low. The high HMGB1 group showed a significantly lower adiponectin level and higher PDMP production than the low HMGB1 group. T2DM risk significantly and positively correlated with HMGB1 and PDMPs. HMGB1-induced PDMP production was simulated in vitro using healthy platelets. Furthermore, The combination of a SGLT2 inhibitor and a DPP-4 inhibitor significantly reduced HMGB1 and PDMP levels. These results suggest that in addition to abnormal glucose metabolism, HMGB1-dependent PDMP production and the resulting development of atherosclerosis are also a concern in patients with T2DM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results